Please login to the form below

Not currently logged in
Email:
Password:

Voyager Therapeutics appoints Matthew Ottmer as chief operating officer

He joins the gene therapy group from Momenta Pharmaceuticals

Matthew OttmerGene therapy focused group Voyager Therapeutics has appointed Matthew Ottmer as its new chief operating officer.

Ottmer has 18 years’ experience in biotechnology, including leadership of business operations, product development, and commercialisation across multiple therapeutic areas.

He said: “I am thrilled to join Voyager at this important time during the company’s evolution.

“Developing and implementing the initial commercial strategy and planning for VY-AADC for Parkinson’s disease is a top priority, especially as we approach the start of the pivotal programme, and I look forward to helping advance our exciting pipeline programmes as well.”

He joins Voyager most recently from Momenta Pharmaceuticals, where he was chief operating officer, responsible for programme and alliance management, research, clinical development, pharmaceutical sciences and commercial activities since late 2015.

Prior to Momenta, Ottmer spent 16 years at Biogen in a variety of leadership roles including senior vice president, strategy and emerging businesses, head of Tysabri business, chief of staff to the chief executive officer and president of Syntonix Pharmaceuticals - a wholly owned subsidiary of Biogen, now Bioverativ - and vice president of global operations.

Steven Paul, president and chief executive officer at Voyager, said: “AS Voyager’s business continues to expand, the fast pace and complexity of our expansion requires additional strong, cross-functional leadership that Matt has demonstrated throughout his career.

“In addition to leading strategy, programme and alliance management, Matt will oversee the commercial development plans of our lead and pipeline programmes.

“We are very excited to welcome Matt to our talented executive leadership team.”

2nd October 2017

From: Sales

Share

Tags

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Weber Shandwick

At Weber Shandwick, engagement has always been the cornerstone of health communications.We make health matter. Health is a basic human...

Latest intelligence

Developing advocacy in the pharmaceutical industry.
The importance of advocacy programmes...
GDPR and events. What does the pharma industry need to know?
Many people in the pharma industry still aren’t following the rules set out by the GDPR when it comes to running events and attending tradeshows. But with eye-watering fines for...
Digital trends in B2B sales - how far behind is Pharma?
The modern approach to B2B sales is data-driven, and enabled by digital tools....

Infographics